Viemed Healthcare, Inc. filings document the public-company reporting of a British Columbia issuer with Nasdaq-listed common shares and a U.S. home-based healthcare business. Recent Form 8-K reports furnish quarterly and annual financial results, financial supplements, guidance updates, investor presentation materials, and Regulation FD disclosures tied to Viemed's home medical equipment and chronic disease management operations.
The filing record also covers capital and governance matters, including a definitive proxy statement with annual meeting, governance, and executive compensation disclosures; credit agreement amendments involving Viemed subsidiaries and lenders; and common-share repurchase authorizations and completed repurchase activity. These filings describe the company's capital structure, material agreements, board actions, and formal disclosure controls around furnished operating updates.
Viemed Healthcare, Inc. reported strong top-line growth for the quarter ended March 31, 2026. Revenue rose to $75.4 million from $59.1 million, driven by broader rental activity and a sharp increase in equipment and supply sales.
Ventilator rentals generated $35.4 million and other home medical equipment rentals $16.2 million, while equipment and supply sales more than doubled to $17.5 million, aided by women’s health products and the Lehan Drugs acquisition. Gross margin was 56.8%, slightly above last year.
Net income attributable to Viemed was $2.6 million, essentially flat year over year, with diluted EPS of $0.06. Operating cash flow improved to $8.1 million, supporting $6.7 million of capital spending and $3.2 million of debt repayment. Cash ended at $9.8 million and total debt at $9.6 million, with shareholders’ equity of $145.8 million.
Viemed Healthcare reported strong first quarter 2026 growth while narrowing and raising its full-year outlook. Net revenue for the quarter ended March 31, 2026 was $75.4 million, up 28% from the prior-year quarter. Net income attributable to Viemed was $2.6 million, or $0.06 per diluted share, and Adjusted EBITDA rose 12% to $14.3 million, despite a non-recurring gain in the prior year.
The company generated $8.1 million of operating cash flow and $2.6 million of free cash flow in the quarter, repurchased 150,000 shares for $1.4 million, and reduced term debt by $3.2 million. Management now expects 2026 net revenue of $312–$320 million, Adjusted EBITDA of $65–$69 million, and lower net capital intensity of 9%–10.5% of net revenue.
Viemed Healthcare, Inc. is calling a 2026 annual general and special meeting to elect seven directors, ratify Ernst & Young LLP as auditor, amend its 2024 Long Term Incentive Plan, and hold a non-binding say‑on‑pay vote.
The equity plan amendment would lift the combined share reserve under current and prior equity plans to 7,696,717 common shares, or 20% of the 38,483,586 shares outstanding as of April 8, 2026. Directors and executive officers together beneficially own 7,912,538 shares, or 20.6% of outstanding shares, while BlackRock, Inc. and Forager Fund, L.P. hold 6.6% and 7.1%, respectively.
Viemed Healthcare, Inc. President Michael Moore reported open-market sales of Common Shares indirectly held through Moore Faster LLC. The LLC sold 31,570 shares on March 18 at a weighted-average price of $9.42, 40,232 shares on March 19 at $9.21, and 65,000 shares on March 20 at $8.77 per share. Footnotes state each reported price is a weighted average for multiple trades in ranges of $9.26–$9.61, $9.04–$9.38, and $8.63–$9.18, respectively. Following these transactions, Moore Faster LLC held 1,585,812 Common Shares indirectly, and Michael Moore also held 189,090 Common Shares directly.
Morgan Stanley Smith Barney LLC submitted a notice under Rule 144 regarding the proposed sale of 65,000 shares of Common stock of the issuer. The filing identifies MOORE FASTER LLC as a selling holder with recent sales reported on 03/19/2026 and 03/18/2026.
The filing lists two recent transactions by MOORE FASTER LLC: 40,232 shares sold on 03/19/2026 and 31,570 shares sold on 03/18/2026, with cash amounts shown alongside each sale.
VMD reported a Form 144 disclosing a sale of 31,570 common shares by MOORE FASTER LLC on 03/18/2026. The reported proceeds were $297,345.20. The transaction lists Morgan Stanley Smith Barney LLC as the broker/financial intermediary.
Viemed Healthcare used a new investor presentation to highlight strong 2025 performance and 2026 guidance. For 2025, the company reported $270M in net revenue, $61M Adjusted EBITDA, $28M free cash flow, nine straight years of positive net income, and effectively $0M net debt.
The business is increasingly diversified, with sleep representing 21% of Q4 2025 net revenue and showing 62% year-over-year growth in PAP therapy patients and 49% growth in sleep resupply patients. Management is guiding 2026 net revenue to $310M–$320M and Adjusted EBITDA to $65M–$69M, with net capex of 10%–11.5% of net revenue.
The company emphasizes a capital-light, home-based care model, expanding from complex ventilation into sleep, oxygen, airway clearance, women’s health and staffing. With more than 172,000 patients across all 50 states, $46M of credit facility availability, and a newly authorized share repurchase program covering up to 5% of shares outstanding, Viemed presents itself as a growth platform supported by regulatory stability and a strong balance sheet.
Viemed Healthcare, Inc. outlines its 2025 annual business profile as a U.S. home medical equipment and post-acute care provider focused on respiratory, chronic care, and women’s health services. The company serves patients in all 50 states through a high-touch, technology-enabled home-care model.
Viemed employed 1,382 people as of December 31, 2025, including 401 licensed respiratory therapists. Monthly ventilator rentals generated about 51% of 2025 revenue, while Medicare and Medicaid together provided 40%. Non-affiliate market value was $238,786,569, with 38,602,631 common shares outstanding.
The report emphasizes heavy dependence on government and commercial reimbursement, extensive U.S. healthcare regulation, fraud and abuse laws, HIPAA privacy and cybersecurity obligations, and evolving Medicare coverage and competitive bidding rules that could materially affect utilization, pricing, and growth, especially for ventilator and home-based respiratory services.
Viemed Healthcare, Inc. outlines its 2025 annual business profile as a U.S. home medical equipment and post-acute care provider focused on respiratory, chronic care, and women’s health services. The company serves patients in all 50 states through a high-touch, technology-enabled home-care model.
Viemed employed 1,382 people as of December 31, 2025, including 401 licensed respiratory therapists. Monthly ventilator rentals generated about 51% of 2025 revenue, while Medicare and Medicaid together provided 40%. Non-affiliate market value was $238,786,569, with 38,602,631 common shares outstanding.
The report emphasizes heavy dependence on government and commercial reimbursement, extensive U.S. healthcare regulation, fraud and abuse laws, HIPAA privacy and cybersecurity obligations, and evolving Medicare coverage and competitive bidding rules that could materially affect utilization, pricing, and growth, especially for ventilator and home-based respiratory services.